155 related articles for article (PubMed ID: 33491942)
1. Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Okauchi S; Shiozawa T; Miyazaki K; Nishino K; Sasatani Y; Ohara G; Kagohashi K; Sato S; Kodama T; Satoh H; Hizawa N
Pol Arch Intern Med; 2021 Feb; 131(2):152-160. PubMed ID: 33491942
[TBL] [Abstract][Full Text] [Related]
2. Association between time to treatment failure and peripheral eosinophils in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Osawa H; Shiozawa T; Okauchi S; Miyazaki K; Kodama T; Kagohashi K; Nakamura R; Satoh H; Hizawa N
Pol Arch Intern Med; 2021 Oct; 131(10):. PubMed ID: 34180611
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takeuchi E; Kondo K; Okano Y; Ichihara S; Kunishige M; Kadota N; Machida H; Hatakeyama N; Naruse K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
Thorac Cancer; 2023 Oct; 14(30):3042-3050. PubMed ID: 37669914
[TBL] [Abstract][Full Text] [Related]
4. Absolute Increase in the Number and Proportion of Peripheral Eosinophils Associated With Immune Checkpoint Inhibitor Treatment in Non-small Cell Lung Cancer Patients.
Osawa H; Shiozawa T; Okauchi S; Sasatani Y; Ohara G; Sato S; Miyazaki K; Kodama T; Kagohashi K; Satoh H; Hizawa N
Cancer Diagn Progn; 2021; 1(5):485-490. PubMed ID: 35403161
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient.
Kagohashi K; Miyazaki K; Shiozawa T; Satoh H
Adv Respir Med; 2021; 89(3):316-319. PubMed ID: 34196384
[TBL] [Abstract][Full Text] [Related]
6. An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takeuchi E; Ogino H; Kondo K; Okano Y; Ichihara S; Kunishige M; Kadota N; Machida H; Hatakeyama N; Naruse K; Nokihara H; Shinohara T; Nishioka Y
Thorac Cancer; 2024 Jan; 15(3):248-257. PubMed ID: 38087769
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
Sherman S; Rotem O; Shochat T; Zer A; Moore A; Dudnik E
Lung Cancer; 2020 May; 143():40-46. PubMed ID: 32203769
[TBL] [Abstract][Full Text] [Related]
8. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD.
Negewo NA; McDonald VM; Baines KJ; Wark PA; Simpson JL; Jones PW; Gibson PG
Int J Chron Obstruct Pulmon Dis; 2016; 11():1495-504. PubMed ID: 27445469
[TBL] [Abstract][Full Text] [Related]
10. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
[TBL] [Abstract][Full Text] [Related]
11. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
Dudnik E; Bshara E; Grubstein A; Fridel L; Shochat T; Roisman LC; Ilouze M; Rozenblum AB; Geva S; Zer A; Rotem O; Allen AM; Peled N
Lung Cancer; 2018 Oct; 124():117-124. PubMed ID: 30268448
[TBL] [Abstract][Full Text] [Related]
12. Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta S; Short SAP; Sise ME; Prosek JM; Madhavan SM; Soler MJ; Ostermann M; Herrmann SM; Abudayyeh A; Anand S; Glezerman I; Motwani SS; Murakami N; Wanchoo R; Ortiz-Melo DI; Rashidi A; Sprangers B; Aggarwal V; Malik AB; Loew S; Carlos CA; Chang WT; Beckerman P; Mithani Z; Shah CV; Renaghan AD; Seigneux S; Campedel L; Kitchlu A; Shin DS; Rangarajan S; Deshpande P; Coppock G; Eijgelsheim M; Seethapathy H; Lee MD; Strohbehn IA; Owen DH; Husain M; Garcia-Carro C; Bermejo S; Lumlertgul N; Seylanova N; Flanders L; Isik B; Mamlouk O; Lin JS; Garcia P; Kaghazchi A; Khanin Y; Kansal SK; Wauters E; Chandra S; Schmidt-Ott KM; Hsu RK; Tio MC; Sarvode Mothi S; Singh H; Schrag D; Jhaveri KD; Reynolds KL; Cortazar FB; Leaf DE;
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625513
[TBL] [Abstract][Full Text] [Related]
13. Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients.
Gobbini E; Charles J; Toffart AC; Leccia MT; Moro-Sibilot D; Levra MG
Bull Cancer; 2020 Nov; 107(11):1098-1107. PubMed ID: 33032816
[TBL] [Abstract][Full Text] [Related]
14. Association between blood eosinophil counts and acute cardiac and pulmonary allograft rejection.
Trull A; Steel L; Cornelissen J; Smith T; Sharples L; Cary N; Stewart S; Large S; Wallwork J
J Heart Lung Transplant; 1998 May; 17(5):517-24. PubMed ID: 9628572
[TBL] [Abstract][Full Text] [Related]
15. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
16. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
[TBL] [Abstract][Full Text] [Related]
17. Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study.
Takayasu S; Mizushiri S; Watanuki Y; Yamagata S; Usutani M; Nakada Y; Asari Y; Murasawa S; Kageyama K; Daimon M
Sci Rep; 2022 Jan; 12(1):1294. PubMed ID: 35079086
[TBL] [Abstract][Full Text] [Related]
18. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
19. Blood eosinophil and monocyte counts are related to smoking and lung function.
Jensen EJ; Pedersen B; Narvestadt E; Dahl R
Respir Med; 1998 Jan; 92(1):63-9. PubMed ID: 9519227
[TBL] [Abstract][Full Text] [Related]
20. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
